1. Home
  2. PNNT vs AGEN Comparison

PNNT vs AGEN Comparison

Compare PNNT & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PennantPark Investment Corporation

PNNT

PennantPark Investment Corporation

HOLD

Current Price

$3.58

Market Cap

251.4M

Sector

Finance

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

N/A

Current Price

$6.94

Market Cap

274.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PNNT
AGEN
Founded
2007
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
251.4M
274.8M
IPO Year
2007
1999

Fundamental Metrics

Financial Performance
Metric
PNNT
AGEN
Price
$3.58
$6.94
Analyst Decision
Hold
Buy
Analyst Count
5
2
Target Price
$5.75
$14.50
AVG Volume (30 Days)
472.1K
996.7K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
20.87%
N/A
EPS Growth
N/A
100.00
EPS
N/A
0.96
Revenue
N/A
$42,877,086.00
Revenue This Year
N/A
$107.63
Revenue Next Year
N/A
N/A
P/E Ratio
$13.14
$7.15
Revenue Growth
N/A
89.95
52 Week Low
$3.19
$2.71
52 Week High
$7.06
$8.85

Technical Indicators

Market Signals
Indicator
PNNT
AGEN
Relative Strength Index (RSI) 42.54 44.89
Support Level $3.31 $2.97
Resistance Level $3.59 $8.70
Average True Range (ATR) 0.09 0.53
MACD -0.03 -0.21
Stochastic Oscillator 6.45 12.37

Price Performance

Historical Comparison
PNNT
AGEN

About PNNT PennantPark Investment Corporation

Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: